Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CARAT

Financiado

Cerrado

Chimeric Antigen Receptors CARs for Advanced Therapies

Chimeric antigen receptors (CARs) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that act as recognition molecules like antibodies or T-cell receptors. In this respect, CARs a... ver más

31/12/2019

MILTENYI BIOTEC BV...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

MILTENYI BIOTEC BV CO KG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-12-31

PHC-16-2015: Tools and technologies for advanced...

I+D

Cerrada hace 10 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

MILTENYI BIOTEC BV CO KG

171.91K€ | Lider

UKLFR

718.58K€ | Participante

TRAKCEL LIMITED

422.75K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SynCAR-Ts Synthetic Chimeric Antigen Receptors: Hijacking Nitrenium Io... 3M€ Cerrado

CARiPSCTcells Generation of safe and efficient off the shelf chimeric an... 166K€ Cerrado

T2EVOLVE Accelerating Development and Improving Access to CAR and TCR... 19M€ Cerrado

CARLY Development and characterization of a novel CAR T-cell thera... 226K€ Cerrado

EURE-CART EURopean Endeavour for Chimeric Antigen Receptor Therapies 6M€ Cerrado

ArTCell Bottom-up manufacturing of artificial anti-tumor T cells 3M€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2015-12-08
Fecha Fin: 2019-12-31

Líder del proyecto

MILTENYI BIOTEC BV CO KG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Chimeric antigen receptors (CARs) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that act as recognition molecules like antibodies or T-cell receptors. In this respect, CARs are increasingly used for cellular therapy to redirect T-cells specifically towards killing of cancer cells. Recent success stories of cancer therapy with CAR modified T-cells have raised enormous scientific and public expectations to cure severely ill patients. However, there are still many obstacles to overcome for translation into clinics because the technology for GMP-compliant manufacture of genetically modified cellular products is extremely complex and expensive. Moreover, CAR therapy needs to be improved with respect to off-target activity, safety and potency. Consequently, the envisaged project is overall aiming at a particular technological breakthrough in cellular cancer therapy by delivering a comprehensive CARAT platform explicitly tailored for automated, easy-to-handle and cost-efficient manufacture of CAR-modified ATMP. Specifically, we aim: (a) to implement unique next-generation cell processing tools like the CliniMACS Prodigy (b) to develop advanced enabling technologies to obtain more effective and safer cellular products by improved gene delivery and innovative CARs design (c) to assemble tools and technologies towards an integrated CARAT process for automated GMP-compliant manufacture of gene-modified T-cells (d) to demonstrate proof-of-concept and regulatory compliance (e) to disseminate broadly applicable, simplified CAR T-cell technologies In summary, our vision is to overcome current hurdles for translation of cellular therapies and to elevate them to the next level of standard-of-care thus serving patients with so far incurable solid tumours and hematologic malignancies. Thereby, we will empower Europe to become a global leader in the development and commercialisation of CAR T-cell tools and technologies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores